SlideShare a Scribd company logo
Anteo Diagnostics Limited (ASX:ADO)
ASX Spotlight Series - New York and London
February/March 2014

Presented by Dr. Geoff Cumming
Managing Director & CEO

“Solid commercial progress and growing revenue streams achieved in 2013 enhance
Anteo’s prospects of becoming cash flow positive in CY2014”
Company Snapshot
Anteo Diagnostics Limited (“Anteo”) is an
Australian biotechnology company that
develops, manufactures and
commercialises proprietary surface
coatings for the global healthcare
industry.

Corporate Snapshot
ADO

Cash

$7.1M

Market Cap.

$134

52 week high

$0.20

52 week low

Major Shareholders

ASX

$0.05

Shares on issue

814.4M

First Cape Mgt Pty Ltd

9.52%

Shareholders

4,414

Austcorp 190 Pty Ltd

4.05%

Top 20

31%

Directors/staff

17%

Nimrod Finance Ltd

2.44%

Board of Directors

Executive Team

Mr. Mark Bouris – Non-Executive Chairman
Dr. Geoff Cumming – Chief Executive Officer
Ms. Sandra (Sam) Andersen – Non-Executive Director
Mr. Richard Martin – Executive Director
Dr. John Hurrell – Non-Executive Director

Dr. Geoff Cumming – Chief Executive Officer
Dr. Joe Maeji – Chief Scientific Officer
Mr. Richard Martin – Chief Financial Officer
Dr. Tina Baumgartner – VP Business Development & Marketing

Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014

2
Recent Highlights
Solid commercial progress and growing revenue streams achieved in 2013…
 Feb 2013
Sales partnership agreement with U.S. based One World Lab
 May 2013
Sales partnership agreement with Spanish based Gennova Scientific for Europe & Latin America
 June 2013
Feasibility agreement with global healthcare company for development of Point of Care device
 June 2013
Granted European Patent on Mix&Go
 July 2013
Received a 2-year $1.7M grant with Commercialisation Australia from April 2013
 November 2013
Heads of Terms signed with BBI Solutions, a global leader in immunoassay development and
manufacturing services

…enhancing the company’s prospects of becoming cash flow positive in CY2014
Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014

3
Mix&Go - Universal Surface Coating
Mix&Go: A Game Changing Product with emerging revenue streams and significant
growth potential
Mix&Go is a specialized universal “glue”:
•

uniquely suited for applications in
diagnostics and life sciences

Mix&Go is applicable to numerous other
large healthcare related segments, e.g.:
•

Separation of proteins and cells

•

Forms ultrathin (< 1nm) layers that bond
strongly

•

Drug discovery and
development

•

Is gentle and does not damage the activity
of fragile biomolecules

•

Medical devices

•

Drug delivery

•

Improves pathology tests  earlier
disease detection

•

Reduces cost of test development and
manufacture (faster/less Ab required)

Mix&Go is well suited to be the “glue” of choice in a variety of applications and industries outside of
healthcare, e.g. Resources and Cleantech

Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014

4
Game Changing Products for Life Sciences

Orientation is
random

3D structure is
damaged

Proprietary solution:
metal polymers

Undamaged,
oriented

Characteristics

Characteristics

Benefits

Vast majority of proteins are nonfunctional

Undamaged, fully functional proteins on
surface

Increased performance
Less non-specific binding
Improved protein stability

More protein (Ab) needed

Less protein and/or beads required

Reduced cost
Saves valuable, expensive proteins

Complicated, time-consuming procedures

Easy and fast to use and manufacture

Improves efficiency
Simpler test procedures
Manufacturing faster, easier, more scalable

Improved reproducibility

Improved accuracy with improved %CV

Expert knowledge needed
Lower sensitivity, LOD, dynamic range

Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014

5
Value Creation and Capture

Large global healthcare markets underpin revenue growth potential
Anteo is targeting large and growing healthcare sectors with Mix&Go. The compelling market opportunities are:
• Laboratory Diagnostics: Encompassing the global IVD market valued at $44 billion in 2011, including the
immunoassay sector at $8.8 billion
• Point-of-Care: Expected size of market by 2017 is $38 billion
• Rapid Test Products: Valued at $3.7 billion in 2012
• Life Science R&D: A very large and diverse $1 billion sector
• Bioseparations: Encompassing protein and protein drug manufacturing sector valued at up to $5 billion

Anteo has multiple and recurring revenue streams including:
• Development Fees: From $250,000+ per full-time employee
• License Fees: From $150,000 + p.a
• Ongoing Royalties: On sales from products containing Mix&Go
Potential royalty earnings vary depending on the size of the company and the degree of benefit Mix&Go can bring.

Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014

6
Milestones 2014
2014

2015

Advancing near-term value accretive opportunities that will translate quickly into revenue….





License and supply agreement with global point-of-care company
Extension of agreement with global lateral flow company
Anteo Mix&Go (AMG) bead and plate products launched in Australia
Pipeline of additional, unique, value-added solutions for the R&D space realised with partners worldwide

Anteo is commencing its next phase of product development
Anteo filed two sets of patent applications in August 2013. These patents will complement the existing Mix&Go patent
portfolio, and expand the protected areas of application to bioseparations, drug screening, drug delivery and areas
outside the health care industry, e.g., in clean tech and resources sectors.

Anteo has 4 advanced projects and ongoing pipeline development. We expect to close
deals with 10 or more medium to large companies during next 4 years.

Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014

7
Bioseparation – Anteo’s Next Opportunity
Current Approach

Paradigm Shift

Chromatography:
•
Time consuming
•
Expensive
•
Hard to automate
•
Capacity constraints

With Mix&Go magnetic separation can become
reality
•
Technically superior solution
•
Economically advantageous

Alternative

Large Opportunities

Magnetic separation:
•
Technically superior
•
Currently unaffordable

•
•
•

Protein and protein drug manufacturing: $35B
Vaccine manufacturing: $620M in 2015
Stem cell therapy market,: $1 B, CAGR 30%

Leverage Mix&Go in bioseparations to create
significant long-term revenue streams for Anteo

Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014

8
Anteo’s Opportunities

Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014

9
Anteo’s Keypoints

 Mix&Go is a proprietary platform technology with broad applicability in
diagnostics, life sciences, bioseparations and beyond

 Mix&Go is proven licensed and gaining significant traction in commercial
markets
 Mix&Go success means Anteo is becoming cash flow positive
 Strong near term value drivers
 Focus on diagnostics and life sciences with expansion into bioseparations
provides Anteo significant revenue opportunities
 Strong leadership - Board and management team in place to drive growth

 Global team, resources and network to capitalise on growth opportunity

Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014

10
Contact Information
Thank you very much for your interest in Anteo Diagnostics
For more information please contact:

Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014

11
Forward Looking Statement

The purpose of the presentation is to provide an update of the business of Anteo Diagnostics (ASX:ADO). These slides have been
prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.
Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements
made by Anteo and should not be relied upon as an independent source of information. Please contact Anteo and/or refer to the
Company's website for further information.
The views expressed in this presentation contain information derived from publicly available sources that have not been
independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.
Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may
prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties
and other factors, many of which are outside Anteo Diagnostics Ltd’s control. Important factors that could cause actual results
to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown
risks. Because actual results could differ materially to assumptions made and Anteo’s current intentions, plans, expectations and
beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Anteo Diagnostics Limited. Nothing in this
presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014

12

More Related Content

PDF
Anteo Diagnostics & Atomo Troponin Lateral Flow test
PDF
Anteo Technologies - New York presentation 2015
PDF
Anteo Diagnostics Research Report November 2015
PDF
Anteo Technologies Investor Presentation
PDF
Aus Biotech 2014 - Anteo Diagnostics
PDF
Anteo Diagnostics Quarterly Report - (ASX : ADO)
PDF
Anteo Diagnostics acquires Diasource
PDF
Anteo Diagnostics to acquire Global Diagnostics Company - Diasource
Anteo Diagnostics & Atomo Troponin Lateral Flow test
Anteo Technologies - New York presentation 2015
Anteo Diagnostics Research Report November 2015
Anteo Technologies Investor Presentation
Aus Biotech 2014 - Anteo Diagnostics
Anteo Diagnostics Quarterly Report - (ASX : ADO)
Anteo Diagnostics acquires Diasource
Anteo Diagnostics to acquire Global Diagnostics Company - Diasource

What's hot (20)

PPTX
DCN Company Profile 2015
PDF
Anteo Diagnostics Microcap Presentation October 2013
PPT
Multiplexing and Arraying in Lateral Flow Assays
PDF
Finnish biotech year, Tero Piispanen
PDF
HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...
PDF
HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen
PDF
HealthBIO 2020_Tero Piispanen_Turku Science Park
PDF
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...
PDF
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
PDF
Experiences from an IPO at AIM, Juho Jalkanen
PDF
HealthBIO 2021,_The InFlames Flagship_Timo Veromaa
PDF
Collaboration through TaNeDS programme, Keiko Tamai
PDF
VTEQ Presentation july 2014
PDF
VeriTeQ Presentation at the Global Online CEO Conference July 2014
PDF
A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...
PDF
Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar
PDF
Innovation drives expansion, Titus Gylvin
PDF
HealthBIO 2020 Aino Kalervo Tilt Biotherapeutics
DCN Company Profile 2015
Anteo Diagnostics Microcap Presentation October 2013
Multiplexing and Arraying in Lateral Flow Assays
Finnish biotech year, Tero Piispanen
HealthBIO 2021_PerkinElmer, leading with innovation - from COVID success into...
HealthBIO 2021_Finnish biotech year 2021_Tero Piispanen
HealthBIO 2020_Tero Piispanen_Turku Science Park
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...
HealthBIO 2021_Orion’s new strategy and industry trends seen from a midsize p...
Experiences from an IPO at AIM, Juho Jalkanen
HealthBIO 2021,_The InFlames Flagship_Timo Veromaa
Collaboration through TaNeDS programme, Keiko Tamai
VTEQ Presentation july 2014
VeriTeQ Presentation at the Global Online CEO Conference July 2014
A Trust-Centric Healthcare Journey Part II | Full Presentation of PharmaLedge...
Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar
Innovation drives expansion, Titus Gylvin
HealthBIO 2020 Aino Kalervo Tilt Biotherapeutics
Ad

Similar to Anteo Diagnostics ASX Spotlight Presentation March 2014 (8)

PPT
Ant Nano presentation to CONNECT North East Conference 09
PDF
PPTX
LED Medical Diagnostics - Investor Presentation April 2014
PPT
Nano diagx product pipeline analysis
PDF
TLSA Investor Presentation August
PDF
TLSA Investor Presentation October
PPTX
Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation
PDF
Erba investor presentation
Ant Nano presentation to CONNECT North East Conference 09
LED Medical Diagnostics - Investor Presentation April 2014
Nano diagx product pipeline analysis
TLSA Investor Presentation August
TLSA Investor Presentation October
Tiziana Life Sciences (NASDAQ: TLSA) Investor Presentation
Erba investor presentation
Ad

More from Matt Sanderson (9)

PDF
Anteo Technologies Lateral Flow
PDF
A Novel Chemistry to Couple Antibodies and Challenging Proteins to Luminex M...
PDF
ASX Australian Biotech Market cap list
PDF
Multiplex energy metabolism
PDF
Novel methods in Bioseparations
PDF
Silicon battery Presentation - Lithium Ion
PDF
Top 10 IVD Companies
PDF
Magnetic-bead-coatings-today-and-tomorrow
PDF
High Sensitivity Troponin
Anteo Technologies Lateral Flow
A Novel Chemistry to Couple Antibodies and Challenging Proteins to Luminex M...
ASX Australian Biotech Market cap list
Multiplex energy metabolism
Novel methods in Bioseparations
Silicon battery Presentation - Lithium Ion
Top 10 IVD Companies
Magnetic-bead-coatings-today-and-tomorrow
High Sensitivity Troponin

Recently uploaded (20)

PDF
202507_Sansan presentation materials FY2024
PPTX
The Future of Philanthropy - AI & Donor Engagement
PDF
TIM Group - Results Presentation H1 '25.pdf
PDF
North Arrow Minerals Corporate and Kraaipan Project Update
PDF
How to Analyze Market Trends in Precious Metal.pdf
PDF
Deutsche EuroShop | Company Presentation | 08/25
PDF
Update on North Arrow Minerals and the Kraaipan Gold Project, Botswanaf
DOCX
How to Avoid Common Crypto Investment Scams.docx
PPTX
办理东北大学毕业证|NEU文凭购买NEU录取通知书2025年新版学位证书
PDF
Cyberagent_For New Investors_EN_250808.pdf
PPTX
TTL1_LMS-Presenfdufgdfgdgduhfudftation.pptx
PPTX
North Arrow Corporate Update for August 5, 2025
PDF
Investor Presentation - Q2 FY 25 - 6 November 2024.pdf
PDF
Probe Gold Corporate Presentation Aug 2025 Final.pdf
DOCX
Security Protocols for Using Trading Signals Safely.docx
PPTX
HealthIllnessSociety.pptxjjjjjjjjjjjjjjjjj
PDF
OR Royalties Inc. - Corporate Presentation, August 2025
PDF
Collective Mining | Corporate Presentation - August 2025
PDF
Methanex Investor Presentation - July 2025
PDF
OR Royalties Inc. - Q2 2025 Results, August 6, 2025
202507_Sansan presentation materials FY2024
The Future of Philanthropy - AI & Donor Engagement
TIM Group - Results Presentation H1 '25.pdf
North Arrow Minerals Corporate and Kraaipan Project Update
How to Analyze Market Trends in Precious Metal.pdf
Deutsche EuroShop | Company Presentation | 08/25
Update on North Arrow Minerals and the Kraaipan Gold Project, Botswanaf
How to Avoid Common Crypto Investment Scams.docx
办理东北大学毕业证|NEU文凭购买NEU录取通知书2025年新版学位证书
Cyberagent_For New Investors_EN_250808.pdf
TTL1_LMS-Presenfdufgdfgdgduhfudftation.pptx
North Arrow Corporate Update for August 5, 2025
Investor Presentation - Q2 FY 25 - 6 November 2024.pdf
Probe Gold Corporate Presentation Aug 2025 Final.pdf
Security Protocols for Using Trading Signals Safely.docx
HealthIllnessSociety.pptxjjjjjjjjjjjjjjjjj
OR Royalties Inc. - Corporate Presentation, August 2025
Collective Mining | Corporate Presentation - August 2025
Methanex Investor Presentation - July 2025
OR Royalties Inc. - Q2 2025 Results, August 6, 2025

Anteo Diagnostics ASX Spotlight Presentation March 2014

  • 1. Anteo Diagnostics Limited (ASX:ADO) ASX Spotlight Series - New York and London February/March 2014 Presented by Dr. Geoff Cumming Managing Director & CEO “Solid commercial progress and growing revenue streams achieved in 2013 enhance Anteo’s prospects of becoming cash flow positive in CY2014”
  • 2. Company Snapshot Anteo Diagnostics Limited (“Anteo”) is an Australian biotechnology company that develops, manufactures and commercialises proprietary surface coatings for the global healthcare industry. Corporate Snapshot ADO Cash $7.1M Market Cap. $134 52 week high $0.20 52 week low Major Shareholders ASX $0.05 Shares on issue 814.4M First Cape Mgt Pty Ltd 9.52% Shareholders 4,414 Austcorp 190 Pty Ltd 4.05% Top 20 31% Directors/staff 17% Nimrod Finance Ltd 2.44% Board of Directors Executive Team Mr. Mark Bouris – Non-Executive Chairman Dr. Geoff Cumming – Chief Executive Officer Ms. Sandra (Sam) Andersen – Non-Executive Director Mr. Richard Martin – Executive Director Dr. John Hurrell – Non-Executive Director Dr. Geoff Cumming – Chief Executive Officer Dr. Joe Maeji – Chief Scientific Officer Mr. Richard Martin – Chief Financial Officer Dr. Tina Baumgartner – VP Business Development & Marketing Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 2
  • 3. Recent Highlights Solid commercial progress and growing revenue streams achieved in 2013…  Feb 2013 Sales partnership agreement with U.S. based One World Lab  May 2013 Sales partnership agreement with Spanish based Gennova Scientific for Europe & Latin America  June 2013 Feasibility agreement with global healthcare company for development of Point of Care device  June 2013 Granted European Patent on Mix&Go  July 2013 Received a 2-year $1.7M grant with Commercialisation Australia from April 2013  November 2013 Heads of Terms signed with BBI Solutions, a global leader in immunoassay development and manufacturing services …enhancing the company’s prospects of becoming cash flow positive in CY2014 Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 3
  • 4. Mix&Go - Universal Surface Coating Mix&Go: A Game Changing Product with emerging revenue streams and significant growth potential Mix&Go is a specialized universal “glue”: • uniquely suited for applications in diagnostics and life sciences Mix&Go is applicable to numerous other large healthcare related segments, e.g.: • Separation of proteins and cells • Forms ultrathin (< 1nm) layers that bond strongly • Drug discovery and development • Is gentle and does not damage the activity of fragile biomolecules • Medical devices • Drug delivery • Improves pathology tests  earlier disease detection • Reduces cost of test development and manufacture (faster/less Ab required) Mix&Go is well suited to be the “glue” of choice in a variety of applications and industries outside of healthcare, e.g. Resources and Cleantech Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 4
  • 5. Game Changing Products for Life Sciences Orientation is random 3D structure is damaged Proprietary solution: metal polymers Undamaged, oriented Characteristics Characteristics Benefits Vast majority of proteins are nonfunctional Undamaged, fully functional proteins on surface Increased performance Less non-specific binding Improved protein stability More protein (Ab) needed Less protein and/or beads required Reduced cost Saves valuable, expensive proteins Complicated, time-consuming procedures Easy and fast to use and manufacture Improves efficiency Simpler test procedures Manufacturing faster, easier, more scalable Improved reproducibility Improved accuracy with improved %CV Expert knowledge needed Lower sensitivity, LOD, dynamic range Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 5
  • 6. Value Creation and Capture Large global healthcare markets underpin revenue growth potential Anteo is targeting large and growing healthcare sectors with Mix&Go. The compelling market opportunities are: • Laboratory Diagnostics: Encompassing the global IVD market valued at $44 billion in 2011, including the immunoassay sector at $8.8 billion • Point-of-Care: Expected size of market by 2017 is $38 billion • Rapid Test Products: Valued at $3.7 billion in 2012 • Life Science R&D: A very large and diverse $1 billion sector • Bioseparations: Encompassing protein and protein drug manufacturing sector valued at up to $5 billion Anteo has multiple and recurring revenue streams including: • Development Fees: From $250,000+ per full-time employee • License Fees: From $150,000 + p.a • Ongoing Royalties: On sales from products containing Mix&Go Potential royalty earnings vary depending on the size of the company and the degree of benefit Mix&Go can bring. Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 6
  • 7. Milestones 2014 2014 2015 Advancing near-term value accretive opportunities that will translate quickly into revenue….     License and supply agreement with global point-of-care company Extension of agreement with global lateral flow company Anteo Mix&Go (AMG) bead and plate products launched in Australia Pipeline of additional, unique, value-added solutions for the R&D space realised with partners worldwide Anteo is commencing its next phase of product development Anteo filed two sets of patent applications in August 2013. These patents will complement the existing Mix&Go patent portfolio, and expand the protected areas of application to bioseparations, drug screening, drug delivery and areas outside the health care industry, e.g., in clean tech and resources sectors. Anteo has 4 advanced projects and ongoing pipeline development. We expect to close deals with 10 or more medium to large companies during next 4 years. Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 7
  • 8. Bioseparation – Anteo’s Next Opportunity Current Approach Paradigm Shift Chromatography: • Time consuming • Expensive • Hard to automate • Capacity constraints With Mix&Go magnetic separation can become reality • Technically superior solution • Economically advantageous Alternative Large Opportunities Magnetic separation: • Technically superior • Currently unaffordable • • • Protein and protein drug manufacturing: $35B Vaccine manufacturing: $620M in 2015 Stem cell therapy market,: $1 B, CAGR 30% Leverage Mix&Go in bioseparations to create significant long-term revenue streams for Anteo Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 8
  • 9. Anteo’s Opportunities Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 9
  • 10. Anteo’s Keypoints  Mix&Go is a proprietary platform technology with broad applicability in diagnostics, life sciences, bioseparations and beyond  Mix&Go is proven licensed and gaining significant traction in commercial markets  Mix&Go success means Anteo is becoming cash flow positive  Strong near term value drivers  Focus on diagnostics and life sciences with expansion into bioseparations provides Anteo significant revenue opportunities  Strong leadership - Board and management team in place to drive growth  Global team, resources and network to capitalise on growth opportunity Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 10
  • 11. Contact Information Thank you very much for your interest in Anteo Diagnostics For more information please contact: Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 11
  • 12. Forward Looking Statement The purpose of the presentation is to provide an update of the business of Anteo Diagnostics (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Anteo and should not be relied upon as an independent source of information. Please contact Anteo and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Anteo Diagnostics Ltd’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Anteo’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. This presentation should not be relied on as a recommendation or forecast by Anteo Diagnostics Limited. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. Anteo Diagnostics Limited I ASX Spotlight Series New York I February 2014 12